Daniel Wadsworth - Arch Therapeutics Advisor Commercialization

All Insiders USA . 
Stock . Arch Therapeutics . Stakeholders . Insider . Daniel Wadsworth
ARTH Stock  USD 0.21  0.01  5.00%   

Insider

Daniel Wadsworth is Advisor Commercialization of Arch Therapeutics
Age 69
Phone617 431 2313
Webhttps://www.archtherapeutics.com

Arch Therapeutics Management Efficiency

The company has return on total asset (ROA) of (1.1363) % which means that it has lost $1.1363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.148) %, meaning that it created substantial loss on money invested by shareholders. Arch Therapeutics' management efficiency ratios could be used to measure how well Arch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Arch Therapeutics currently holds 2.81 M in liabilities with Debt to Equity (D/E) ratio of 2.62, implying the company greatly relies on financing operations through barrowing. Arch Therapeutics has a current ratio of 0.8, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Arch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Keith SimeoneSTRATA Skin Sciences
N/A
Darrell RigelSTRATA Skin Sciences
73
Richard AregladoBrainsway
60
Pr ZangenBrainsway
54
Rajiv SilvaVenus Concept
57
Kenji ShimizuVenus Concept
71
Jonathan ParisRapid Micro Biosystems
48
MD ODonnellTactile Systems Technology
N/A
Jennifer ErnstTivic Health Systems
56
Robert MocciaSTRATA Skin Sciences
65
Moria AnkriBrainsway
40
Domenic PennaVenus Concept
62
Sanjay AhujaTivic Health Systems
N/A
Ronen CPAIcecure Medical
55
Nikolai KabelevSTRATA Skin Sciences
48
Shay LevavIcecure Medical
47
Eyal ShamirIcecure Medical
63
Victoria VezinaRapid Micro Biosystems
56
William MBASTRATA Skin Sciences
58
Naum MuchnikIcecure Medical
48
Veronica CaiTivic Health Systems
48
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people. Arch Therapeutics [ARTH] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-40.15
Return On Asset-1.14

Arch Therapeutics Leadership Team

Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Abrams, Chief Officer
Daniel Yrigoyen, VP Sales
Terrence MD, Chairman, CoFounder
Daniel Wadsworth, Advisor Commercialization
Steven Kates, VP Technology
Rutledge EllisBehnke, CoFounder Advisor

Arch Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Arch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-40.15
Return On Asset-1.14
Operating Margin(364.73) %
Current Valuation12.54 M
Shares Outstanding249.94 M
Shares Owned By Insiders14.58 %
Price To Earning(16.36) X
Price To Book34.61 X
Price To Sales638.65 X
Revenue15.65 K

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Arch OTC Stock

Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY